デフォルト表紙
市場調査レポート
商品コード
1236867

糖尿病網膜症市場:世界の産業動向、シェア、規模、成長、機会、2023-2028年予測

Diabetic Retinopathy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

出版日: | 発行: IMARC | ページ情報: 英文 142 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
糖尿病網膜症市場:世界の産業動向、シェア、規模、成長、機会、2023-2028年予測
出版日: 2023年02月21日
発行: IMARC
ページ情報: 英文 142 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の糖尿病網膜症の市場規模は、2022年に76億米ドルに達しました。今後、IMARC Groupは、2023年から2028年の間に6.1%の成長率(CAGR)を示し、2028年までに108億米ドルに達すると予測しています。

糖尿病網膜症(DR)とは、糖尿病によって網膜の血管に生じる障害を指します。この病気は、非増殖性DRと増殖性または進行性DRの2種類に分けられます。血糖値の変動により、目の中の光に敏感な組織が異常に増殖することで起こります。DRの症状としては、視野に暗い斑点や浮き糸が見える、視界がぼやける、変動する、色覚が損なわれる、視力が低下するなどがあります。フルオレセイン血管造影や光干渉断層計などの検査で診断でき、治療には、眼内ステロイド注射、レーザー治療、硝子体手術などが行われます。

糖尿病の有病率の増加や、世界の老齢人口の増加が、市場の成長を促進する主な要因となっています。さらに、糖尿病による失明の発生率が高まっていることも、市場の成長を後押ししています。利用可能な治療法およびDRの早期発見の利点について、大衆の間で認識が高まっています。その結果、改良された眼科診断機器や手術機器など、技術的に高度な処置や機器が広く採用されるようになりました。これらの処置や機器は、早期発見と効率的な治療を可能にし、より高い精度で、患者の不快感を最小限に抑えます。その他の要因としては、医療費の増加、高度な医療サービスを大衆に提供するための有利な政府政策の実施、大規模な研究開発活動などがあり、市場をさらに牽引すると予測されます。

主要市場のセグメンテーション

  • IMARC Groupは、世界の糖尿病網膜症市場レポートの各サブセグメントにおける主要動向の分析と、2023年から2028年までの世界、地域、国レベルでの予測を提供します。当レポートでは、市場をタイプ別、治療タイプ別、エンドユーザー別に分類しています。

本レポートで回答した主な質問

  • 世界の糖尿病網膜症市場はこれまでどのように推移し、今後数年間はどのように推移するのか?
  • 主要な地域市場とは?
  • COVID-19が世界の糖尿病網膜症市場に与えた影響は?
  • タイプに基づく市場の内訳は?
  • 治療タイプに基づく市場の内訳は?
  • エンドユーザー別の市場内訳は?
  • 業界のバリューチェーンにおける様々なステージとは?
  • 業界における主要な促進要因と課題は何か?
  • 世界の糖尿病網膜症市場の構造と主要プレイヤーは?
  • 業界における競合の程度は?

目次

第1章 序文

第2章 範囲と調査手法

  • 調査目的
  • 利害関係者について
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主な業界動向

第5章 糖尿病網膜症の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響について
  • 市場予測

第6章 タイプ別市場内訳

  • 増殖性糖尿病網膜症
    • 市場の動向
    • 市場予測
  • 非増殖性網膜症
    • 市場動向について
    • 市場予測

第7章 治療タイプ別市場内訳

  • 抗VEGF薬
    • 市場動向について
    • 市場予測
  • ステロイドインプラント
    • 市場動向について
    • 市場予測
  • レーザー手術
    • 市場動向について
    • 市場予測
  • 硝子体手術
    • 市場動向について
    • 市場予測

第8章 エンドユーザー別市場内訳

  • 病院・薬局の場合
    • 市場の動向
    • 市場予測
  • 眼科医院
    • 市場の動向
    • 市場予測
  • 外来手術センター(ASC)
    • 市場の動向
    • 市場予測
  • その他
    • 市場の動向
    • 市場予測

第9章 地域別市場内訳

  • 北米
    • 米国
      • 市場の動向
      • 市場予測
    • カナダ
      • 市場の動向
      • 市場予測
  • アジア太平洋地域
    • 中国
      • 市場動向について
      • 市場予測
    • 日本
      • 市場動向について
      • 市場予測
    • インド
      • 市場動向について
      • 市場予測
    • 韓国
      • 市場動向について
      • 市場予測
    • オーストラリア
      • 市場の動向
      • 市場予測
    • インドネシア
      • 市場の動向
      • 市場予測
    • その他
      • 市場の動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場の動向
      • 市場予測
    • フランス
      • 市場の動向
      • 市場予測
    • 英国
      • 市場の動向
      • 市場予測
    • イタリア
      • 市場動向について
      • 市場予測
    • スペイン
      • 市場動向について
      • 市場予測
    • ロシア
      • 市場動向について
      • 市場予測
    • その他
      • 市場動向について
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向について
      • 市場予測
    • メキシコ
      • 市場動向について
      • 市場予測
    • その他
      • 市場の動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場の動向
    • 国別の市場内訳
    • 市場予測

第10章 SWOT分析

  • 概要
  • ストレングス
  • 弱点
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターズファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の度合い
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 競合情勢について

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Alimera Sciences
    • Allergan Plc
    • Ampio Pharmaceuticals
    • Bayer Healthcare
    • BCN Peptides
    • Genentech
    • Kowa Group
    • Novartis AG
    • Regeneron Pharmaceuticals Inc.
    • Sirnaomics Inc.
図表

List of Figures

  • Figure 1: Global: Diabetic Retinopathy Market: Major Drivers and Challenges
  • Figure 2: Global: Diabetic Retinopathy Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Diabetic Retinopathy Market: Breakup by Type (in %), 2022
  • Figure 4: Global: Diabetic Retinopathy Market: Breakup by Treatment Type (in %), 2022
  • Figure 5: Global: Diabetic Retinopathy Market: Breakup by End-User (in %), 2022
  • Figure 6: Global: Diabetic Retinopathy Market: Breakup by Region (in %), 2022
  • Figure 7: Global: Diabetic Retinopathy Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 8: Global: Diabetic Retinopathy (Proliferative Diabetic Retinopathy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Diabetic Retinopathy (Proliferative Diabetic Retinopathy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Diabetic Retinopathy (Non-proliferative Retinopathy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Diabetic Retinopathy (Non-proliferative Retinopathy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Diabetic Retinopathy (Anti VEGF Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Diabetic Retinopathy (Anti VEGF Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Diabetic Retinopathy (Steroid Implants) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Diabetic Retinopathy (Steroid Implants) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Diabetic Retinopathy (Laser Surgeries) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Diabetic Retinopathy (Laser Surgeries) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Diabetic Retinopathy (Vitrectomy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Diabetic Retinopathy (Vitrectomy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Diabetic Retinopathy (Hospitals and Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Diabetic Retinopathy (Hospitals and Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Diabetic Retinopathy (Eye Clinics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Diabetic Retinopathy (Eye Clinics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Diabetic Retinopathy (Ambulatory Surgical Centres-ASCs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Diabetic Retinopathy (Ambulatory Surgical Centres-ASCs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Diabetic Retinopathy (Others) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Diabetic Retinopathy (Others) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: North America: Diabetic Retinopathy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: North America: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: United States: Diabetic Retinopathy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: United States: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Canada: Diabetic Retinopathy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Canada: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: Asia Pacific: Diabetic Retinopathy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: Asia Pacific: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: China: Diabetic Retinopathy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: China: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Japan: Diabetic Retinopathy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Japan: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: India: Diabetic Retinopathy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: India: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: South Korea: Diabetic Retinopathy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: South Korea: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Australia: Diabetic Retinopathy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Australia: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: Indonesia: Diabetic Retinopathy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: Indonesia: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: Others: Diabetic Retinopathy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: Others: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Europe: Diabetic Retinopathy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Europe: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Germany: Diabetic Retinopathy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Germany: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: France: Diabetic Retinopathy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: France: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: United Kingdom: Diabetic Retinopathy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: United Kingdom: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Italy: Diabetic Retinopathy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Italy: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: Spain: Diabetic Retinopathy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: Spain: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Russia: Diabetic Retinopathy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Russia: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Others: Diabetic Retinopathy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Others: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Latin America: Diabetic Retinopathy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Latin America: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Brazil: Diabetic Retinopathy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Brazil: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Mexico: Diabetic Retinopathy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Mexico: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Others: Diabetic Retinopathy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Others: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: Middle East and Africa: Diabetic Retinopathy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 75: Middle East and Africa: Diabetic Retinopathy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 76: Global: Diabetic Retinopathy Industry: SWOT Analysis
  • Figure 77: Global: Diabetic Retinopathy Industry: Value Chain Analysis
  • Figure 78: Global: Diabetic Retinopathy Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Diabetic Retinopathy Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Diabetic Retinopathy Market Forecast: Breakup by Type (in Million US$), 2023-2028
  • Table 3: Global: Diabetic Retinopathy Market Forecast: Breakup by Treatment Type (in Million US$), 2023-2028
  • Table 4: Global: Diabetic Retinopathy Market Forecast: Breakup by End-User (in Million US$), 2023-2028
  • Table 5: Global: Diabetic Retinopathy Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Diabetic Retinopathy Market: Competitive Structure
  • Table 7: Global: Diabetic Retinopathy Market: Key Players
目次
Product Code: SR1523A132_Report

The global diabetic retinopathy market size reached US$ 7.6 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 10.8 Billion by 2028, exhibiting a growth rate (CAGR) of 6.1% during 2023-2028.

Diabetic retinopathy (DR) refers to the damage caused to the blood vessels in the retina by diabetes mellitus. This ailment is of two kinds, namely non-proliferative DR and proliferative or advanced DR. It is caused by fluctuations in the blood glucose levels resulting in an abnormal growth in the light-sensitive tissues present in the eye. The symptoms of DR include the visibility of dark spots or floating strings in the vision field, blurred or fluctuating vision, impaired color vision or loss of vision. It can be diagnosed through tests, such as fluorescein angiography and optical coherence tomography, and the treatment involves the use of intraocular steroid injection, laser treatment and vitrectomy.

The increasing prevalence of diabetes, along with the growing geriatric population across the globe, represent as the key factors driving the growth of the market. Furthermore, the rising incidence of blindness caused by DR is also providing a boost to the market growth. There is an increasing awareness among the masses regarding the available treatment alternatives and the benefits of early detection of DR. This has resulted in the widespread adoption of technologically advanced procedures and equipment, such as the improved ophthalmic diagnostic and surgical instruments. These procedures and equipment enable early detection and efficient treatment of the ailment with higher precision and minimal discomfort to the patient. Other factors, including the increasing healthcare expenditures, the implementation of favorable government policies to make advanced healthcare services available to the masses and extensive research and development (R&D) activities, are projected to drive the market further.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global diabetic retinopathy market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, treatment type and end-user.

Breakup by Type:

  • Proliferative Diabetic Retinopathy
  • Non-proliferative Retinopathy

Breakup by Treatment Type:

  • Anti VEGF Drugs
  • Steroid Implants
  • Laser Surgeries
  • Vitrectomy

Breakup by End-User:

  • Hospitals and Pharmacies
  • Eye Clinics
  • Ambulatory Surgical Centres (ASCs)
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

  • The competitive landscape of the industry has also been examined with some of the key players being Alimera Sciences, Allergan PLC, Ampio Pharmaceuticals, Bayer Healthcare, BCN Peptides, Genentech, Kowa Group, Novartis AG, Regeneron Pharmaceuticals Inc., Sirnaomics Inc., etc.

Key Questions Answered in This Report:

  • How has the global diabetic retinopathy market performed so far and how will it perform in the coming years?
  • What are the key regional markets?
  • What has been the impact of COVID-19 on the global diabetic retinopathy market?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the treatment type?
  • What is the breakup of the market based on the end-user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global diabetic retinopathy market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Diabetic Retinopathy Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Proliferative Diabetic Retinopathy
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Non-proliferative Retinopathy
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Treatment Type

  • 7.1 Anti VEGF Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Steroid Implants
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Laser Surgeries
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Vitrectomy
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by End-User

  • 8.1 Hospitals and Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Eye Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Ambulatory Surgical Centres (ASCs)
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Alimera Sciences
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
    • 13.3.2 Allergan Plc
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Ampio Pharmaceuticals
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
    • 13.3.4 Bayer Healthcare
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 BCN Peptides
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
    • 13.3.6 Genentech
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 SWOT Analysis
    • 13.3.7 Kowa Group
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
    • 13.3.8 Novartis AG
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
    • 13.3.9 Regeneron Pharmaceuticals Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Sirnaomics Inc.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio